Developer docs
API playgroundTry for free, no card

Search company profiles

Gore Range Capital

Full company profile

uuid0003kjd

Namestring
Gore Range Capital
Legal namestring
Gore Range Capital LLC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Gore Range Capital is a specialized healthcare venture capital firm founded in 2015 by Ethan Rigel and Humberto Antunes, initially based in New York and relocated to Southlake, Texas (Dallas-Fort Worth) in 2020–2021 to align with the regional skin-health cluster anchored by Galderma. The firm invests in early-stage healthcare companies developing next-generation platforms across precision health, regenerative medicine, personalized therapeutics, longevity, and aesthetic dermatology, framing skin as a biological gateway to broader healthspan applications. Its investment thesis spans six ecosystem verticals — devices, diagnostics, enhancement, regeneration, treatment, and prevention — with check sizes typically between $5 million and $15 million per company at pre-approval or Phase I/II development stages.

The firm does not develop proprietary technology; rather, it sources and supports science-led portfolio companies through a combination of direct capital, strategic guidance, and clinical validation via a seven-member Scientific Advisory Board chaired by Dr. Darrell Rigel and including dermatologists from Harvard, NYU, UCLA, and the University of Miami. Notable portfolio companies include Palvella Therapeutics (QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (aesthetic dermatology including AI-09 neuromodulator and ET-02 hair-loss therapy), Novaestiq Corp. (Saypha injectable HA gels with Croma-Pharma, sold to Waldencast in July 2025), Sagesse Bio (RNAi focal-fat-reduction JV with Sirnaomics), AOA Dx (ovarian cancer liquid biopsy), and Avive Solutions (connected AED devices). Historical exits include BioXcel Therapeutics (~$60M IPO) and Castle Biosciences (~$64M IPO).

Gore Range generates revenue through standard VC economics: management fees on committed capital across Fund I (closed early 2019) and Fund II (nine-figure, nearly committed), plus carried interest on portfolio exits. The firm employs approximately 5 core investment professionals plus a CFO and senior advisors, and is reportedly evaluating a third fund to extend its skin-health-focused strategy. Customer concentration is moderate, with check sizes diversified across roughly 20 investments and six historical exits spanning biopharma, aesthetics, diagnostics, devices, and digital health.

Short descriptiontext

Gore Range Capital is a New York- and Southlake, Texas-based healthcare venture capital firm founded in 2015 that invests $5M–$15M in early-stage skin-health, regenerative medicine, and longevity companies, serving portfolio founders and limited partners through its Fund I and nine-figure Fund II.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, skin health investing, early-stage biotech, life sciences venture, longevity investments
Industry2 codes
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
SECONDARYFSANAHAA
Strategic / Balance-Sheet CVC (On-balance-sheet investing)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Healthcare Investment
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Management Fees and Carried Interest
TypeLicensing Royalties
Description

As a venture capital firm formed in 2015, Gore Range Capital generates revenue through management fees on committed capital and carried interest (performance fees) from successful portfolio company exits. Fund II is a nine-figure fund with second fund nearly committed.

gorerangecapital.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gore Range Capital is a specialized healthcare venture capital firm that makes early-stage equity investments (typically $5M–$15M) into companies developing science-led platforms in precision health, regenerative medicine, personalized therapeutics, longevity, and skin health. The firm combines private equity operational discipline with a venture-style scientific partnership model, providing portfolio companies with strategic, financial, and clinical guidance across pre-approval and Phase I/II trial stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20 investments made across funds with 6 successful exits
+2 more records
Product overview1 text field

Gore Range Capital is a specialized healthcare venture capital firm focused on skin health investments. The firm does not offer products or services directly; rather, it invests in portfolio companies developing healthcare solutions in precision health, regenerative medicine, personalized therapeutics, longevity, and restorative medical sciences. The portfolio includes companies such as Palvella Therapeutics (developing QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (developing aesthetic dermatology products like ET-02 for hair loss), Sagesse Bio (developing SGY-101 for focal fat reduction), Novaestiq (developing Saypha injectable hyaluronic acid gels), and Avive Solutions (developing connected AED devices).

Product and service2 records
1Gore Range Capital Fund I
CategoryVenture Capital Fund
Description

Venture capital fund providing early-stage equity investments and operational support to healthcare companies focused on skin health and adjacent therapeutic areas. Target investors are limited partners seeking exposure to specialized healthcare innovation.

2Gore Range Capital Fund II
CategoryVenture Capital Fund
Description

Second venture capital fund of nine-figure size, making direct equity investments of $5M–$15M into early-stage healthcare companies developing next-generation skin health, precision health, regenerative medicine, and longevity platforms. Aimed at limited partners seeking returns from a focused dermatology and longevity thesis.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Dermatology Summit / Advancing Innovation in Dermatology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-11
Description

Humberto Antunes serves as member of Dermatology Summit Conference Board of Directors & Advisors and will moderate two sessions at 2026 summit in San Francisco including panels on dermatology business in Asia and challengers in aesthetic medicine.

gorerangecapital.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-07-23
Description

Acquired Novaestiq Corp. (GRC Fund II portfolio company) in exchange for upfront cash, royalties in perpetuity based on net sales, and contingent issuance of up to 9.8M Waldencast class A shares on FDA approval and sales milestones. Novaestiq's Saypha injectables will be launched under Obagi Medical brand.

3Croma-Pharma GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-15
Description

Joint venture partner in Novaestiq Corp., developing injectable hyaluronic acid gels (Saypha ChIQ and Saypha MagIQ) for US market. Croma brings 40 years of HA-based treatment expertise with over 110 million syringes produced and marketing in 80+ countries. Novaestiq was sold to Waldencast in July 2025 for combination of upfront cash, royalties, and contingent shares.

gorerangecapital.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-05
Description

Strategic partnership to create Sagesse Bio, combining GRC's skin health expertise with Sirnaomics' cutting-edge RNAi technology to accelerate clinical development of novel solutions for focal fat reduction. Sirnaomics provides RNAi technology platform and scientific expertise; GRC contributes industry knowledge and operational support. Lead compound SGY-101 is IND-enabled and in Phase II clinical trials for other indications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage life sciences venture firm that backs clinical-stage biopharmaceutical companies, often with a focus on specific therapeutic verticals. Directly comparable to Gore Range in fund size, stage focus (Phase I/II assets), and the operating-partner model that supports portfolio companies through clinical development.

TypeDirect peer
Description

Early-stage life sciences VC that builds and funds biotech companies from inception through clinical proof-of-concept. Comparable to Gore Range in targeting pre-approval and early clinical assets, providing operating support, and creating companies around specific scientific platforms.

TypeDirect peer
Description

Healthcare-dedicated venture firm with deep dermatology and therapeutics expertise stemming from the Index Ventures life sciences franchise. Closely comparable to Gore Range's specialized dermatology/skin health investment focus and early-stage clinical asset strategy.

TypeDirect peer
Description

Early-stage life sciences VC investing in platform technologies and therapeutic assets at the preclinical-to-clinical inflection point. Directly comparable to Gore Range's $5-15M check size at key growth inflection points and hands-on operating partnership model.

TypeDirect peer
Description

Early-stage science and healthcare VC that creates and funds companies from breakthrough university and corporate research. Comparable to Gore Range's model of co-creating companies with strategic partners (e.g., Sirnaomics, Croma-Pharma) and supporting assets from inception through clinical milestones.

TypeDirect peer
Description

Healthcare-dedicated investment firm with both venture and growth funds covering therapeutics, medical devices, and diagnostics. Comparable to Gore Range's specialist healthcare mandate, with similar investment stages and operating-partner support for portfolio companies.

TypeDirect peer
Description

Healthcare-focused venture firm investing across therapeutic platforms, medical devices, and diagnostics from clinical development through commercialization. Directly comparable to Gore Range's clinical-stage focus and specialty healthcare model.

TypeBroad incumbent
Description

One of the largest healthcare-dedicated investment firms globally, with multi-stage funds spanning venture, growth, and public equities across therapeutics, devices, and diagnostics. A broad incumbent operating in the same dermatology and aesthetics space but at materially larger fund sizes and broader mandate than Gore Range.

TypeBroad incumbent
Description

One of the largest and most active venture capital firms with a longstanding healthcare and life sciences practice spanning biotech, medtech, and healthtech. A broad incumbent that competes for healthcare assets but at much larger fund sizes and across a far broader sector mandate than Gore Range's dermatology-focused thesis.

TypeDirect peer
Description

Life sciences-focused investment firm with clinical translation and venture funds targeting therapeutics and digital health. Comparable to Gore Range's stage focus (early clinical through development), specialist healthcare mandate, and operating-partner engagement model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment19 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gore Range Capital

Venture Capital / Healthcare Investmentgorerangecapital.com

Gore Range Capital is a New York- and Southlake, Texas-based healthcare venture capital firm founded in 2015 that invests $5M–$15M in early-stage skin-health, regenerative medicine, and longevity companies, serving portfolio founders and limited partners through its Fund I and nine-figure Fund II.

What Gore Range Capital does

Gore Range Capital is a specialized healthcare venture capital firm founded in 2015 by Ethan Rigel and Humberto Antunes, initially based in New York and relocated to Southlake, Texas (Dallas-Fort Worth) in 2020–2021 to align with the regional skin-health cluster anchored by Galderma. The firm invests in early-stage healthcare companies developing next-generation platforms across precision health, regenerative medicine, personalized therapeutics, longevity, and aesthetic dermatology, framing skin as a biological gateway to broader healthspan applications. Its investment thesis spans six ecosystem verticals — devices, diagnostics, enhancement, regeneration, treatment, and prevention — with check sizes typically between $5 million and $15 million per company at pre-approval or Phase I/II development stages.

The firm does not develop proprietary technology; rather, it sources and supports science-led portfolio companies through a combination of direct capital, strategic guidance, and clinical validation via a seven-member Scientific Advisory Board chaired by Dr. Darrell Rigel and including dermatologists from Harvard, NYU, UCLA, and the University of Miami. Notable portfolio companies include Palvella Therapeutics (QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (aesthetic dermatology including AI-09 neuromodulator and ET-02 hair-loss therapy), Novaestiq Corp. (Saypha injectable HA gels with Croma-Pharma, sold to Waldencast in July 2025), Sagesse Bio (RNAi focal-fat-reduction JV with Sirnaomics), AOA Dx (ovarian cancer liquid biopsy), and Avive Solutions (connected AED devices). Historical exits include BioXcel Therapeutics (~$60M IPO) and Castle Biosciences (~$64M IPO).

Gore Range generates revenue through standard VC economics: management fees on committed capital across Fund I (closed early 2019) and Fund II (nine-figure, nearly committed), plus carried interest on portfolio exits. The firm employs approximately 5 core investment professionals plus a CFO and senior advisors, and is reportedly evaluating a third fund to extend its skin-health-focused strategy. Customer concentration is moderate, with check sizes diversified across roughly 20 investments and six historical exits spanning biopharma, aesthetics, diagnostics, devices, and digital health.

Gore Range Capital firmographics

Firmographics
Name
Gore Range Capital
Legal name
Gore Range Capital LLC
Website
https://gorerangecapital.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Gore Range Capital is a New York- and Southlake, Texas-based healthcare venture capital firm founded in 2015 that invests $5M–$15M in early-stage skin-health, regenerative medicine, and longevity companies, serving portfolio founders and limited partners through its Fund I and nine-figure Fund II.
Ownership category
akta.pro rank

Gore Range Capital industry classification

Industry
Product category
Venture Capital / Healthcare Investment
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
SECONDARYFSANAHAA
Strategic / Balance-Sheet CVC (On-balance-sheet investing)

Keywords

  • Healthcare venture capital
  • Skin health investing
  • Early-stage biotech
  • Life sciences venture
  • Longevity investments

Where Gore Range Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Gore Range Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees and Carried Interest: As a venture capital firm formed in 2015, Gore Range Capital generates revenue through management fees on committed capital and carried interest (performance fees) from successful portfolio company exits. Fund II is a nine-figure fund with second fund nearly committed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Gore Range Capital product offering

Product offering

Core offering

Gore Range Capital is a specialized healthcare venture capital firm that makes early-stage equity investments (typically $5M–$15M) into companies developing science-led platforms in precision health, regenerative medicine, personalized therapeutics, longevity, and skin health. The firm combines private equity operational discipline with a venture-style scientific partnership model, providing portfolio companies with strategic, financial, and clinical guidance across pre-approval and Phase I/II trial stages.

Product overview

Gore Range Capital is a specialized healthcare venture capital firm focused on skin health investments. The firm does not offer products or services directly; rather, it invests in portfolio companies developing healthcare solutions in precision health, regenerative medicine, personalized therapeutics, longevity, and restorative medical sciences. The portfolio includes companies such as Palvella Therapeutics (developing QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (developing aesthetic dermatology products like ET-02 for hair loss), Sagesse Bio (developing SGY-101 for focal fat reduction), Novaestiq (developing Saypha injectable hyaluronic acid gels), and Avive Solutions (developing connected AED devices).

Differentiator

Problem solved

Functional benefit

Products and services

  • Gore Range Capital Fund I Venture capital fund providing early-stage equity investments and operational support to healthcare companies focused on skin health and adjacent therapeutic areas. Target investors are limited partners seeking exposure to specialized healthcare innovation.
  • Gore Range Capital Fund II Second venture capital fund of nine-figure size, making direct equity investments of $5M–$15M into early-stage healthcare companies developing next-generation skin health, precision health, regenerative medicine, and longevity platforms. Aimed at limited partners seeking returns from a focused dermatology and longevity thesis.

Quantifiable outcome

  • 20 investments made across funds with 6 successful exits
  • +2 more outcomes

Companies that use Gore Range Capital

Customer profile

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Gore Range Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gore Range Capital partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Dermatology Summit / Advancing Innovation in DermatologyminorStrategic or Co-development Partner · 11 January 2026Humberto Antunes serves as member of Dermatology Summit Conference Board of Directors & Advisors and will moderate two sessions at 2026 summit in San Francisco including panels on dermatology business in Asia and challengers in aesthetic medicine.
  • Waldencast plccoreGTM or Marketing Partner · 23 July 2025Acquired Novaestiq Corp. (GRC Fund II portfolio company) in exchange for upfront cash, royalties in perpetuity based on net sales, and contingent issuance of up to 9.8M Waldencast class A shares on FDA approval and sales milestones. Novaestiq's Saypha injectables will be launched under Obagi Medical brand.
  • Croma-Pharma GmbHcoreStrategic or Co-development Partner · 15 August 2024Joint venture partner in Novaestiq Corp., developing injectable hyaluronic acid gels (Saypha ChIQ and Saypha MagIQ) for US market. Croma brings 40 years of HA-based treatment expertise with over 110 million syringes produced and marketing in 80+ countries. Novaestiq was sold to Waldencast in July 2025 for combination of upfront cash, royalties, and contingent shares.
  • SirnaomicscoreStrategic or Co-development Partner · 5 August 2024Strategic partnership to create Sagesse Bio, combining GRC's skin health expertise with Sirnaomics' cutting-edge RNAi technology to accelerate clinical development of novel solutions for focal fat reduction. Sirnaomics provides RNAi technology platform and scientific expertise; GRC contributes industry knowledge and operational support. Lead compound SGY-101 is IND-enabled and in Phase II clinical trials for other indications.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Gore Range Capital competitors and assessment

Company assessment

Direct peers

  • venBio: Early-stage life sciences venture firm that backs clinical-stage biopharmaceutical companies, often with a focus on specific therapeutic verticals. Directly comparable to Gore Range in fund size, stage focus (Phase I/II assets), and the operating-partner model that supports portfolio companies through clinical development.
  • Atlas Venture: Early-stage life sciences VC that builds and funds biotech companies from inception through clinical proof-of-concept. Comparable to Gore Range in targeting pre-approval and early clinical assets, providing operating support, and creating companies around specific scientific platforms.
  • Medicxi: Healthcare-dedicated venture firm with deep dermatology and therapeutics expertise stemming from the Index Ventures life sciences franchise. Closely comparable to Gore Range's specialized dermatology/skin health investment focus and early-stage clinical asset strategy.
  • 5AM Ventures: Early-stage life sciences VC investing in platform technologies and therapeutic assets at the preclinical-to-clinical inflection point. Directly comparable to Gore Range's $5-15M check size at key growth inflection points and hands-on operating partnership model.
  • ARCH Venture Partners: Early-stage science and healthcare VC that creates and funds companies from breakthrough university and corporate research. Comparable to Gore Range's model of co-creating companies with strategic partners (e.g., Sirnaomics, Croma-Pharma) and supporting assets from inception through clinical milestones.
  • Frazier Healthcare Partners: Healthcare-dedicated investment firm with both venture and growth funds covering therapeutics, medical devices, and diagnostics. Comparable to Gore Range's specialist healthcare mandate, with similar investment stages and operating-partner support for portfolio companies.
  • Domain Associates: Healthcare-focused venture firm investing across therapeutic platforms, medical devices, and diagnostics from clinical development through commercialization. Directly comparable to Gore Range's clinical-stage focus and specialty healthcare model.
  • Abingworth: Life sciences-focused investment firm with clinical translation and venture funds targeting therapeutics and digital health. Comparable to Gore Range's stage focus (early clinical through development), specialist healthcare mandate, and operating-partner engagement model.

Broad incumbents

  • OrbiMed: One of the largest healthcare-dedicated investment firms globally, with multi-stage funds spanning venture, growth, and public equities across therapeutics, devices, and diagnostics. A broad incumbent operating in the same dermatology and aesthetics space but at materially larger fund sizes and broader mandate than Gore Range.
  • New Enterprise Associates (NEA): One of the largest and most active venture capital firms with a longstanding healthcare and life sciences practice spanning biotech, medtech, and healthtech. A broad incumbent that competes for healthcare assets but at much larger fund sizes and across a far broader sector mandate than Gore Range's dermatology-focused thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Gore Range Capital social profiles

Digital presence

Gore Range Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gore Range Capital leadership team

Management profile

Number of profiles

Profiles7 records

Gore Range Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gore Range Capital M&A and investment

M&A and investment

M&A

Investments19 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gore Range Capital

What does Gore Range Capital do?

Gore Range Capital is a specialized healthcare venture capital firm that makes early-stage equity investments (typically $5M–$15M) into companies developing science-led platforms in precision health, regenerative medicine, personalized therapeutics, longevity, and skin health. The firm combines private equity operational discipline with a venture-style scientific partnership model, providing portfolio companies with strategic, financial, and clinical guidance across pre-approval and Phase I/II trial stages.

Is Gore Range Capital a public or private company?

Gore Range Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Gore Range Capital founded?

Gore Range Capital was founded in 2015. It employs 1 to 10 people.

Where is Gore Range Capital based?

Gore Range Capital is headquartered in New York, United States, in the North America region.

How does Gore Range Capital make money?

One revenue line is on record: management Fees and Carried Interest.

Who are Gore Range Capital's main competitors?

Direct peers on record are venBio, Atlas Venture, Medicxi, 5AM Ventures, ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates and Abingworth. Broad incumbents are OrbiMed and New Enterprise Associates (NEA).

Does Gore Range Capital have an API?

No public API is recorded for Gore Range Capital.

What industry is Gore Range Capital in?

Gore Range Capital's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing, with a secondary code of FSANAHAA, Strategic / Balance-Sheet CVC (On-balance-sheet investing). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCroma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins WaldencastWaldencast plc has acquired Novaestiq Corp., a joint venture between Croma-Pharma GmbH and Gore Range Capital, as part of its strategy to expand in the aesthetic medicine sector. This acquisition enables the upcoming U.S. launch of Croma-Pharma's Saypha® hyaluronic acid injectables under the Obagi Medical brand, with products currently awaiting FDA approval. The move reinforces Croma-Pharma's international growth objectives while leveraging Waldencast's platform for scaling beauty and wellness brands.YahooGore Range Capital Partners with Sirnaomics to Create Sagesse Bio to Advance RNAi Therapeutics for Focal Fat Reduction and Aesthetic Body ContouringGore Range Capital and Sirnaomics formed Sagesse Bio to develop RNAi therapeutics for focal fat reduction and aesthetic body contouring. The medical aesthetics market is projected to grow from $20 billion to $27 billion by 2028. Sagesse Bio will begin clinical evaluation of its product candidate SGY-101.PR NewswireSirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic MedicineSirnaomics Ltd. has partnered with Gore Range Capital LLC to establish a joint venture, Sagesse Bio, Inc., focused on advancing its RNAi therapeutic products into aesthetic medicine applications such as body contouring and fat reduction. Under the agreement, Sirnaomics will receive milestone payments of up to US$33 million and a majority equity position in Sagesse Bio valued at approximately US$36 million, with the venture having a minimum pre-financing valuation of US$60 million. Sagesse Bio will advance Sirnaomics' IND-enabled lead compound SGY-101, currently in Phase II clinical trials, with initial indications targeting focal fat destruction and body contouring.Business Wire BlogRenowned Dermatologist - Dr. Matt Leavitt joins Gore Range Capital as an Executive PartnerDr. Matt Leavitt, founder of Advanced Dermatology and Cosmetic Surgery, joined Gore Range Capital as Executive Partner. He brings expertise in dermatology and aesthetic medicine, having founded multiple companies in the skin health space. The addition aims to strengthen Gore Range's focus on skin health, aging, and wellness.Dallas InnovatesHere's Why This Southlake-Based VC Is Investing in the Future of Skin HealthGore Range Capital, a venture capital firm specializing in skin health innovations, has launched its second fund following the successful closure of its debut fund in 2019. The firm, now headquartered in Southlake, Texas, focuses on early-stage investments in dermatological treatments and technologies while leveraging its operational expertise to guide portfolio companies toward exit. Managing Partner Ethan Rigel recently shared strategic advice for founders regarding risk management, capital raising, and partnership structures.PR NewswireAlgeness® von Advanced Aesthetic Technologies, Inc. als Top-Finalist im renommierten Terra2 Solution Skin Health Innovation Wettbewerb ausgewähltAdvanced Aesthetic Technologies, Inc. (AAT) and its flagship product Algeness® were selected as one of two top finalists in the Terra2 Solutions Skin Health Innovation Competition, finishing as the best aesthetic innovation and second overall at the global event held during the 18th Annual Winter Clinical Dermatology Conference-Hawaii. The competition, organized by Gore Range Capital in partnership with Terra2 Solutions and DermX Media Group, featured expert judges from clinical dermatology, aesthetic medicine, and healthcare IT. AAT is a Brookline, Massachusetts-based company developing injectable gel implant dermal fillers, with Algeness® currently CE-marked and available in over 30 countries while the company pursues FDA approval in the US and registration in China through partnerships with Lanzhou Biotechnique Development Co., LTD.American City Business JournalsSouthlake VC firm Gore Range Capital eyes early-stage skin health startups with new fundGore Range Capital, a Southlake VC firm, is launching a new fund to invest in early-stage skin health startups. The fund aims to return to the firm's roots by focusing on this sector.FinSMEsGore Range Closes Debut Healthcare Venture Capital FundGore Range Capital, a New York-based healthcare venture firm, closed its first fund to further external capital. The firm has made 13 investments with two successful exits and one IPO, including BioXcel Therapeutics, CoreMedica Labs, and Or-Genix Therapeutics.